KRIYA-748 / Kriya Therap - LARVOL DELTA

Assay Validation and Clinical Sample Stability of Recombinant AAV Vector in Five Human Shedding Matrices (ASGCT 2024) - "KRIYA-748 is an AAV-based vector that delivers a gated ion channel to the trigeminal nerve for trigeminal neuralgia, a disease characterized by frequent, debilitating facial pain attacks. Once expressed, the channel is activated by orally-administered varenicline ("Chantix®") leading to reduced excitation of transduced neurons... Ten validation runs were performed with serially diluted DNA standards, negative controls, and QCs, plated in the presence of DNA extracted from each of the shedding matrices evaluated. Each completed run met the validation acceptance criteria for target gene amplification. The ULOQ, LLOQ, and LOD were 108, 50, and 10 double stranded copies per reaction, respectively."

Clinical • Gene Therapies • Neuralgia • Pain